Human hepatitis B virus (HBV) is one of the causative agents of hepatocellular carcinoma (HCC). The virus encodes a 17 kDa protein, X, which is known to be a causative agent in the formation of HCC. An insulin-like growth factor-II (IGF-II) is expressed during the formation of HCC. Among the four promoters of the IGF-II gene, promoters 2, 3 and 4 become activated during the formation of HCC. The high frequency of detection of hepatitis B virus X (HBV-X) antigen in liver cells from patients with chronic hepatitis, cirrhosis, and liver cancer suggested that the expressions of HBV-X and IGF-II are associated. Studies were carried out to test the relationship between the HBV-X gene product and the activation of IGF-II promoter 4. We demonstrated that the HBV-X protein increases the endogenous IGF-II expression from promoter 3 and 4 of IGF-II gene. Analysis of the fourth promoter of IGF-II gene showed that the HBV-X gene product positively regulates transcription. Two copies of a motif are responsible for conferring HBV-X regulation on the fourth promoter of IGF-II. These motifs have been identi®ed as Sp1 binding sites. Sp1 binding to IGF-II P4 promoter was identi®ed by gel mobility shift assay using puri®ed Sp1. By using a GAL4-Sp1 fusion protein it was demonstrated that HBV-X positively regulates the Sp1 mediated transcriptional activity of IGF-II in vivo. A protein-anity chromatography experiment showed that HBV-X protein does not bind directly to Sp1, but HBV-X does augment the DNA binding activity of the phosphorylated form of Sp1 in HepG2 cells. Sp1 was phosphorylated by HBV-X and its DNA-binding activity was up-regulated upon HBV-X transfections. Various HBV-X mutant expression vectors were used for the demonstration of speci®c interactions between Sp1 and HBV-X. These results indicate that HBV-X functions as a positive regulator of transcription, and that Sp1 is a direct target for the transcriptional regulation of IGF-II. Increasing the DNA binding ability of the phosphorylated form of Sp1 by HBV-X might be an important mechanism for regulating the IGF-II gene expression and possibly promoting cell division during hepatic carcinogenesis. Our experimental results suggest that expression of HBV-X might induce the expression of IGF-II and the IGF-II might play a role in hepatitis B virus pathogenesis during the formation of HCC.
Introduction
During cell transformation and tumor development, autocrine or paracrine production of growth factor by certain cells is involved (Sporn and Roberts, 1985) . In the liver, insulin-like growth factor-II (IGF-II), originally called somatomedin A, is believed to function by autocrine or paracrine mechanisms of growth control in hepatocytes during malignant transformation (Daughaday and Rotwein, 1989) . The IGF-II transcripts synthesized at high levels in human and rodent fetal livers are overexpressed in certain embryonic tumors (Gray et al., 1987; Lamas et al., 1989; Scott et al., 1985) .
Transcription of the human IGF-II gene is regulated by activation of four dierent promoters which act in a tissue-speci®c and development-dependent manner (Holthuizen et al., 1990) . Promoter 1 becomes activated in adult liver tissue while promoters 2, 3, and 4 become activated in fetal liver tissue (Holthuizen et al., 1990) . Under the control of these four dierent promoters, human IGF-II gene yields six kinds of mRNA species. In human adult liver tissue, a 5.3 kb mRNA species is dominant, while two other species of mRNA, 6.0 kb and 4.8 kb, are dominant in many fetal liver and non-hepatic tissues (Holthuizen et al., 1990; Soars et al., 1985) . Increasing levels of the fetal form of IGF-II transcripts have been reported in HCCs from woodchucks (Fu et al., 1988) , rats (Frunzio et al., 1986) and humans (Cariani et al., 1988) . In addition, recent in situ hybridization results have demonstrated the presence and upregulation of the fetal form IGF-II mRNA transcripts in hepatocytes from human HCCtissue (Carolyn et al., 1991) .
IGF-II involvement in hepatic cell proliferation may be triggered by HBV or chemical carcinogens (Carolyn et al., 1991) . Fu et al. identi®ed increased IGF-II expression in primary liver tumors infected with WHV, while the presence of HBV transcripts and increased IGF-II transcripts in human peritumoral tissue has been reported in human HCCs (Cariani et al., 1988; Fu et al., 1988) .
Using immunohistochemical methods, Carolyn et al. demonstrated that in human HCCs arising from cirrhosis or noncirrhotic chronic liver disease with HBV involvement showed increased expression of IGF-II mRNA transcripts (Carolyn et al., 1991) . These ®ndings imply a role for HBV in IGF-II expression regulation in primary liver cancers. In the case of woodchuck hepatitis virus induced HCC studies by Yang et al. (Yang and Rogler, 1991; Yang et al., 1993) showed that IGF-II production is a regular accompaniment of hepatic oncogenesis and it has been suggested that IGF-II production by the tumor might be an important autocrine proliferative signal. Among the four gene products, HBsAg, HBcAg, HBxAg and polymerase, encoded by the four ORFs in HBV, which is an etiological agent of acute and chronic hepatitis in man, HBxAg is a protein, approximately 154 amino acids long, which has been detected with high frequency in liver cells with chronic hepatitis, cirrhosis and liver cancer. It was ®rst reported by Twu and Schloemer as a transcriptional transactivator for expression of the cellular gene of interferon-b .
The HBV-X activates a wide variety of dierent enhancer/promoters, from homologous viral promoters, such as C, S and X promoters coupled to the HBV enhancer and heterologous viral promoters (Seto et al., 1988; Spandau and Lee, 1988; . Cellular promoters are also transactivated by X-Ag (Yoo et al., 1996) . Stimulation of these promoters by HBV-X is mediated by indirect mechanisms involving the activation of cellular transcription factors, including AP1, AP2, and NF-kB (Natori et al., 1994; Seto et al., 1990; and many other transcription factors without binding to the Xresponse element on DNA. HBV-X forms proteinprotein complexes with cellular transcription factors, such as CREB and ATF-2, and modi®es their ability to bind transcriptional enhancers (Maguire et al., 1991) . Several reports also suggested that the HBV-X stimulates transcription through direct interactions at the promoter with a component of the transcription machinery (Cheong et al., 1995; Quadri et al., 1995) . On the other hand, HBV-X acts indirectly through cellular signaling pathways (Benn and Schneider, 1994; Kekule et al., 1993) . Other studies also suggested that HBV-X might act on the proteolytic degradation pathways of the cell (Takada et al., 1994) or it may interact with p53 (Wang et al., 1994) . Recently, it has been shown that the woodchuck hepatitis B virus X gene is important for the establishment of viral infection in woodchucks, suggesting that the HBV-X gene also plays an important role in HBV replication in humans (Chen et al., 1993) . Studies were carried out to test the relationship between the HBV-X product and activation of the fourth promoter of theIGF-II gene, which is activated during the formation of HCCs. In this study we demonstrated that transcription from the fourth promoter of the IGF-II gene is stimulated by HBV-X. The HBV-X transactivate IGF-II promoter 4 through the two Sp1 binding sites. The HBV-X does not bind to Sp1 directly while HBV-X phosphorylates Sp1 which resulted in an increased binding of the phosphorylated form of Sp1 to its target DNA and eventually activates transcriptions. These results suggested that HBV-X is able to regulate transcription in a positive manner through a modi®cation of the speci®c transcription factor. Taken together, our results suggested that HBV-X might play an important role in activating IGF-II transcription during the formation of HCC.
Result

HBV-X activates IGF-II expression
To examine whether the HBV-X regulates the activity of the IGF-II promoter, we tested the expression of the IGF-II mRNA in ®ve dierent cell lines; rhabdomyosarcoma (RD), HepG2, Hep3B, HBV-X transiently transfected HepG2 (HepG2(X)) and HBV-X permanently expressing HepG2 (HepG2-4X) cell lines ( Figure  1A) . We chose the RD cell line as a positive control which exhibited large amounts of endogeneous levels of IGF-II mRNA. mRNA was isolated as described (Daughaday et al., 1989) . Ten micrograms of isolated mRNAs were used for Northern analysis using a fulllength human IGF-II cDNA fragment as a probe. Northern analysis results of the RD cell line showed high level expression of IGF-II mRNA ( Figure 1Aa , lane 1) while Hep3B and HepG2 cells showed a low expression level ( Figure 1Aa , lanes 2 and 3). Transcripts derived from promoter 3 (6.0 Kb) and promoter 4 (4.8 Kb) were detected (Daughaday et al., 1989) . The HBV-X transiently expressing cell line showed a twofold increase in the expression of IGF-II transcripts while the HBV-X permanently expressing cell line showed a fourfold increase of the IGF-II transcripts. (Figure 1Aa, lanes 4 and 5, 1Ab) . These results showed that the HBV-X can increase the IGF-II transcripts in transiently expressing or permanently expressing cell lines implying that the HBV-X increases the endogeneous IGF-II expression from promoter 3 and 4. To examine the stimulation eect of HBV-X on transcription of the IGF-II promoter 4 in dierent cell lines, 10 mg of wild type IGF-II promoter-CAT construct (pIG0) was cotransfected with 5 mg of the control expression vector (pMAM), or a human HBV-X expression vector (pMAM-HX) in the A549, Hep3B, PLC/PRF/5, and HepG2 cell lines ( Figure 1B) .
In all four cell lines the CAT activity was increased by HBV-X more than the control expression vector (pMAM). These results show that HBV-X transactivates the IGF-II promoter 4 not only in hepatoblastoma cell lines (Hep3B, HepG2, PLC/PRL/5) but also in the adenocarcinoma (A549) cell line, indicating that HBV-X transactivation of the IGF-II promoter 4 is a general phenomena in all cell lines.
Mapping of the HBV-X responsive element in the p4 promoter of the IGF-II gene
To determine whether HBV-X regulates the IGF-II p4 promoter in a manner similar to that of c-fos, c-myc, and many other viral promoters, a construct containing the p4 promoter fused to the bacterial CAT, pIG0CAT was used.
To determine the X-responsive element (XRE) sequences in the promoter-4, 5'-deletions of the promoter were constructed (Hyun et al., 1993) , and these plasmids were used for cotransfection of HepG2 cells. The plasmids were cotransfected with either a control expression plasmid (pMAM) or the human HBV-X expression vector (pMAM-HX) into the hepatoblastoma cell line, HepG2. The level of CAT activity was determined 48 h after transfection. The activities of constructs pIG0(7411), pIG1(7311), pIG2(7213), pIG5(7111), pIG6(772), pIG7(758), pIG8(736), and pIG9 (722) showed 34.37, 12.47, 20.07, 10.67, 18.97, 9.87, 1.17 , and 1.1-fold induction, respectively, by X (Figure 2 ). Induction by HBV-X dropped to the basal level when deletion (Kim et al., 1992) .
Stimulation of the P4 promoter of the IGF-II gene by Sp1
To determine whether Sp1 binds to IGF-II P4 promoter, puri®ed Sp1 protein was used in a gel shift analysis using the pIG5, pIG7 and pIG8 promoter fragments as probes ( Figure 3a ). As shown in Figure 3a , Sp1 binds with a high anity to pIG5 and pIG7 probes but does not bind to the pIG8 probe. To determine directly whether the IGF-II P4 promoter was involved in mediating Sp1-directed transcription, the eect of Sp1 on transcription was examined in Drosophila melanogaster SL2 (Schneider) cells. The IGF-II CAT chimeric constructs were cotransfected with a Drosophila actin promoter-Sp1 expression vector (pSp1) (Kim et al., 1992) , and the level of CAT activity was determined ( Figure 3b ). The activities of constructs pIG0, pIG5, pIG6, and pIG7 were induced 74.8-, 72.1-, 71.2-, and 70.4-fold respectively, by Sp1, whereas the activity of pIG8 was induced only 5.0-fold. These ®ndings suggest that the Sp1 site is located between 758 and 736 in the IGF-II P4 promoter and Sp1 can bind to this fragment, while the bound Sp1 is transcriptionally active.
HBV-X regulates expression of the IGF-II gene through Sp1
Since the sequences between 758 and 736, which showed HBV-X-responsiveness to the IGF-II p4 promoter, contain two Sp1 binding sites, the importance of these binding sites for HBV-X activity was investigated. To examine the role of the Sp1 binding sites in HBV-X mediated transcriptional regulation, both Sp1 binding sites were inactivated by changing the three internal base pairs of each site (Figure 4a , m3). Since both of the Sp1 binding sequences (GGGTGG) showed variations of the Sp1 consensus binding sequences (GGGCGG), a single T(m1, m2) and both T(m4) of the variant Sp1 sites were changed into C, in order to test the ability of the Sp1 consensus binding (GGGCGG) sequences to confer HBV-X mediated transcriptional regulation (Figure 4a ). The eect of HBV-X on the Sp1 binding site mutants was examined by cotransfection of the plasmid into HepG2 cells with and without an HBV-X expression vector (Figure 4b ). Mutant construct m1, m2, and m4 activities were induced 18-to 25-fold by Sp1, whereas m3 was induced only 1.1-fold. Thus, the change of GGGTGG to the consensus Sp1 binding site GGGCGG had no eect on the ability of Sp1 to activate transcription, whereas inactivation of both Sp1 sites abolished Sp1 activation. These results suggest that HBV-X can stimulate transcription of the IGF-II P4 promoter through the Sp1 binding sites. In the IGF-II P4 promoter the GGGTGG Sp1 binding sites and the consensus Sp1 binding site GGGCGG conferred equal responsiveness to HBV-X. HBV-X can regulate transcription through the Sp1 binding site. However, it is possible that other factors that can bind to the XRE sequence of the IGF-II P4 promoter can mediate the eect of HBV-X on transcription. A plasmid construct (pSG147+Sp1N) which expresses a GAL4-Sp1 fusion protein under the regulation of the SV40 early promoter (Figure 5a ) was used to verify the Sp1 mediated transcriptional activation of HBV-X. Since the zinc ®nger DNA-binding domain of Sp1 was deleted (Sp1N), the Gal4-Spl fusion protein was dependent upon the GAL4 DNA binding domain for DNA binding. A CAT reporter construct (pG5BCAT) containing ®ve GAL4 binding sites upstream from the E1B TATA box was used to determine the eect of X on GAL4-Sp1 mediated transcription. The reporter construct pG5BCAT, the GAL4-Sp1 expression construct (pSG147+Sp1N), and either the HBV-X expression plasmid (pMAM-HX) or a control vector (pMAM) were cotransfected into HepG2 cells. As shown in Figure 5b , the coexpression of HBV-X signi®cantly stimulated Sp1 mediated transcription in HepG2 cells (compare lanes 1 and 2). As a control, HBV-X did not stimulate pG5BCAT expression in the presence of the GAL4 DNA binding domain alone (pSG 147: compare lanes 3 and 4). The GAL4-VP1 fusion protein (pSG147+VP1) which contained the activation domain of GAL4 was used as a positive control. These results directly implicate Sp1 as component in conferring HBV-X mediated transcriptional regulation.
Sp1 can not associate with HBV-X
To investigate whether Sp1 associates with HBV-X, we used protein-anity chromatography. We used a bacterial expression vector in which the glutathione-Stransferase (GST) gene is linked to a DNA fragment encoding a HBV-X gene (pGST-X). Sp1 expression vector (pSp1) transfected Schneider cell extracts or p53 expression vector (pCMVp53) transfected HepG2 cell extracts were incubated with glutathione-agarose beads containing immobilized GST or GST-X. Bound proteins were eluted from the column with glutathione Ten mg of pG5BCAT, 4 mg of PMAMneo, 2 mg of pSG147+VP1, and 10 mg of either pMAM or pMAM-HX were cotransfected into HepG2 cells. pSV-GH (1 mg) was used as an internal control for transfection eciency (Kim et al., 1992) . The amount of extract in lanes 3 and 4 increased twofold, where as the amount of extract used in lanes 5 and 6 was reduced twofold to obtain CAT activity within the linear range and the presence of Sp1 proteins in the elute was assessed by immunoblotting. Results shown in Figure  6a validate the speci®city of the Sp1, p53 and HBV-X antibodies used in these experiments. The Sp1, p53 and HBV-X speci®c antibodies recognized Sp1 in Sp1 expressed Schneider cell extracts (Figure 6a -1), p53 in p53 expressed HepG2 cell extracts (Figure 6a -2) and E. coli derived GST-X fusion protein and puri®ed HBV-X-protein ( Figure 6A-3 ). Figure 6b shows the results of the protein-anity chromatography experiments. In Figure 6b -1, the Sp1-antibody reacted with 97 kDa polypeptide of the cell extracts prepared from Sp1 transfected Scheider cells (lane 1). As shown in lanes 3 and 4, GST-X¯ow through eluent (lane 3) showed reactivity with Sp1-antibody, while GST-X bound (lane 4) did not show reactivity, indicating that HBV-X does not bind with Sp1. In lane 2, GST was used for the negative control. For the positive control, HBV-X and p53 binding were tested using a GST-X column (Figure 6b -2). Figure 6b -2, lane 4 showed that p53 binds to the GST-X anity column while in lane 3, which were the¯ow through of the p53 expressed cell extracts, does not show any binding with X. In lane 2, GST was used as the negative control. In lane 1, p53 protein was used as a positive control. Thus, these results clearly demonstrate that HBV-X can not associate with Sp1.
Induction of Sp1 binding to Sp1 consensus sequences by pX in HepG2 cells
Modulation of Sp1 directed transcription by HBV-X is a complex phenomena which depends on the signals that modulate the intrinsic transcriptional activity or the DNA-binding activity of the transcription factor Sp1. We tested the ability of HBV-X to modulate the Sp1 DNA binding activity. Because of the small percentage of the cells which are transfected by Xexpression vector (pMAM-X), we not only used the Xtransfected HepG2 cells (HepG2 (X)) but also the Xexpressing cell line (HepG2-4X) which constitutively expressed large quantities of HBV-X. First, the nuclear extracts from HepG2, HepG2(X) and HepG2-4X were checked for binding activity to Sp1 consensus sequences of IGF-II promoter 4 ( Figure  7a, lanes 2, 3 and 4) . In lane 1, control Sp1 was bound with Sp1 probe, while in lane 2, HepG2 nuclear extracts were bound with Sp1 probe. Three predominant protein-DNA complexes in vitro with nuclear extracts were found (Sp1, I and II bands) ( Figure 7a , lane 2). These are similar to RCE complexes previously shown to be regulated by RB (Kim et al., 1992) . The Sp1 probe binding activity of nuclear extracts from HepG2 cells transfected with HBV-X and constitutive HBV-X expressing cell lines, were compared to that of In transiently HBV-X transfected HepG2 cells (HepG2(X)) or constitutive HBV-X producing HepG2 cells (HepG2-4X), the Sp1 binding to its consensus DNA probe increased compared to the untransfected HepG2 cells (Figure 7a, lanes 3 and 4) . Besides Sp1, bands I and II also increase in HepG2(X) and HepG2-4X cell lines compared to the untransfected HepG2 cell (Figure 7a, lanes 3 and 4) . By adding Sp1 antibody, we also demonstrated the supershift band of Sp1 in three dierent cell lines (Figure 7a , lanes 5, 6 and 7). Competition experiments with increased amounts of unlabelled Sp1 oligonucleotide showed a gradual decrease of the retarded bands (I, II) including the Sp1 band (Figure 7a , lanes 8 ± 11). These results suggest that a common set of nuclear factors can interact with Sp1 consensus sequence within a IGF-II promoter 4.
In order to check whether there are actual amounts of Sp1 increase in HepG2, HepG2(X) or HepG2-4X cells, immunoblotting experiments using HepG2, HepG2(X), HepG2-4X nuclear extracts and Sp1 polyclonal antibodies were done (Figure 7b ). No dierences in the amounts of Sp1 in the extracts obtained from the three dierent cell lines were detected (Figure 7b) . Thus, at least under our experimental conditions, pX does not increase the actual amount of Sp1 in the cells. These results indicate that in the presence of similar amounts of Sp1, X might induce posttranslational modi®cations that renders the Sp1 complex more ecent in its DNA-binding ability. To determine if any of the retarded bands shown in Figure 7a , represent Sp3 as well as Sp1, gel shift analyses were performed in the presence of speci®c anti-Sp1 or anti-Sp3 antibodies. In the presence of Sp1-speci®c antibodies, the slowest migrating complex is supershifted ( Figure  7c , lane 2). When the anti-Sp3 antibody was present in the binding reaction, the other two complexes (I and II) were shifted ( Figure 7c , lane 3) but the slowest migration complex was unaltered. This suggests that the band I and band II complex represent the binding of proteins antigenically related to Sp3. Band I and II possibly represent Sp3 and a recently described alternatively translated product of the full-length Sp3 (Legget et al., 1995) . These results demonstrated that Sp1 and Sp3 can both bind to Sp1 consensus sequences in IGF-II promoter 4. 
HBV-X stimulates Sp1 phosphorylation
Since HBV-X induced the Sp1 binding to Sp1 consensus sequences in HepG2 cells, we investigated whether HBV-X aected Sp1 phosphorylation, which might be a cause of the increase of Sp1 binding to its consensus DNA sequences. Schneider cells which lack Sp1 were transfected with Sp1 expression vector(pSp1) and X expression vector(pCMV⋅X) and in vivo labeled with 32 P-orthophosphate. The cells were lysed, nuclear extracts were prepared and Sp1 was precipitated with Sp1 antibody. After running on 8% SDS ± PAGE, the gel was autoradiographed. The results in Figure 8a showed that, X-phosphorylates Sp1 (lane 1) while Schneider cell nuclear extracts, which were not transfected with X, showed basal levels of the phosphorylated band (lane 2). HepG2, HepG2(X) and HepG2-4X cells were also labeled with 32 P-orthophosphate. The cells were lysed, nuclear extracts were prepared and Sp1 was precipitated with Sp1 antibody. The results shown in Figure 8b indicate that HBV-X transiently or permanently expressed cells increased the phosphorylation state of Sp1. HepG(X) and HepG2-4X cells showed a four-and ®vefold increase in phosphorylations of Sp1 over control levels, respectively. In order to re-con®rm the phosphorylation of Sp1 by HBV-X, immunoblot analysis was performed on nuclear extracts prepared from Schneider cells transfected with HBV-X or untransfected cell lines. Nuclear extracts from HBV-X transfected or untransfected cell lines were treated with calf intestine phosphatase (CIP) and compared with CIP untreated cell extracts. The results shown in Figure 8C , lane 2 demonstrate that phosphorylated Sp1 was present in HBV-X transfected HepG2 cells while only Sp1 protein was present on CIP treated (lane 1) or HBV-X untransfected HepG2 cells (lanes 3 and 4). These results clearly showed that HBV-X protein phosphorylate Sp1, in vivo.
Proteins binding to Sp1 consensus sites are modi®ed by phosphorylation
In order to con®rm whether post-translational modi®cations, especially phosphorylation, were reponsible for the enhanced binding of the proteins to Sp1 consensus sequences of IGF-II promoter 4, dephosphorylation of Hep2, HepG2(X) and HepG2-4X nuclear extracts using calf intestine phosphatase was carried out. Gel-shift assays were performed using Sp1 consensus sequences as probes. As can be seen in Figure 9 , dephosphorylation of extracts from all three cell lines resulted in the formation of weak protein-DNA complexes (Sp1, I and II (Sp3)) ( Figure 9 , lanes 2, 7 and 12), compared to the calf intestine phosphatase untreated cell line extracts (Figure 8 , lanes 1, 6 and 11). The inclusion of phosphatase inhibitors in dephosphorylation reaction eciently blocked the induction of protein-DNA complexes ( Figure 9, lanes 3, 8 and 13 ) which indicates that these changes were dependent on the action of phosphatase. The supershifted band by anti-Sp1 (Figure 9 , lanes 5, 10 and 15) also showed weak protein-DNA complexes after being treated with calf intestine phosphatase, compared to the untreated protein-DNA complexes (Figure 9 , lanes 4, 9 and 14).
Eect of Sp-1 mediated transcription on HBV-X mutants in HepG2 cells
To identify the regions of HBV-X required for Sp1 mediated transactivation of the IGF-II promoter 4, a series of X-mutants were constructed (Figure 10a ). Five N-terminal and four C-terminal deletion mutants of the HBV-X protein were made . Mutant transactivation activites were determined from CAT activities after co-transfection of respective X- 
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Sp1. (c) Immunoblot analysis of HBV-X transfected cells on Sp1 protein levels. 100 mg of nuclear extracts from pSp1 transfected or pSp1, pCMV-X double transfected Schneider cells were (1 unit/50 mg protein, BM cpy) dephosphorylated (lanes 1 and 3) using calf intestine alkaline phosphatase or untreated (lanes 2 and 4). Sp1 protein from CIP treated or untreated nuclear extracts was immunoblotted using polyclonal Sp1 antibodies (Santa Cruz cpy). Sp1 and phosphorylated Sp1 were indicated (Sp1 and Sp1)
* P * P * P mutant expression constructs, and the GAL4-Sp1 expression construct with the reporter pG5B-CAT plasmid into HepG2 cells. The CAT activities of each mutant were compared with the wild type. Experiments were repeated three times with quantitatively similar results. Sp1 mediated transcriptional activation was diminished in successive deletions of the N-terminal and Cterminal regions of the X-protein ( Figure 10A ). In the N-terminal deletion mutant, removal of 9 amino acids did not have any aect on its ability to transactivate Sp1 mediated transactivation in HepG2 cells. Rather, the transactivation activities of the ND-1 mutant Xprotein were increased compared to the wild type Xprotein, in agreement with a recent report that the ®rst 20 N-terminal amino acids in the X-sequence might contribute a repressor eect on X-transactivations (Murakami et al., 1994) . Larger, internal deletions extending from amino acids 2 to 27(ND-2), amino acids 2 to 40(ND-3), and amino acids 2 to 52(ND-3) resulted in an 18*31% activity decrease compared to the wild type. However, deletions of amino acids 2*70 from the X-ORF encoded by ND-5 showed a 77% decrease of X-activity. These results are consistant with those of Ritter et al. (1991) who reported that deletions of amino acids 32 to 66 resulted in the loss of almost all pSVCAT reporter activity.
In the analysis of C-terminal deletion mutants, amino acids 136*154 could be deleted from HBV-X without aecting its ability to transactivate Sp1 mediated transcription (Figure 10a ). However, more than 75% loss of the HBV-X transactivating eect was identi®ed in CD-3 and CD-4. These results appear to be due to the removal of an additional 5 amino acids (V, F, V, L, G) from CD-2 (amino acids 131*135) (Figure 10a and b) .
Discussion
Elevated levels of IGF-II mRNA are present in a variety of human tumors where it functions as an autocrine or parcrine growth stimulator. In the present study, we investigated the activation of human IGF-II P4 promoter by HBV-X in a hepatoblastoma cell line. Our data have shown that HBV-X activates both endogeneous and transfected IGF-II P4 promoter. This raises the possibility that during the HBV infection into the hepatocytes or the precursor oval cells, the HBV-X might be partially responsible for IGF-II overexpression or reexpression that endows the cells with a proliferative advantage which eventually leads to liver cirrhosis and hepatocellular carcinoma. We demonstrated that HBV-X activates IGF-II P4 promoter through Sp1 binding sites. Sp1 binding to IGF-II P4 promoter and Sp1 mediated transcriptional activation by HBV-X were demonstrated. HBV-X does not form complexes with Sp1; instead HBV-X phosphorylate Sp1 and increased the DNA binding activity of the phosphorylated form of Sp1 to its target DNA sequence. The HBV-X induced malignant transformation of mouse hepatocytes (Hohne et al., 1990 ) and NIH3T3 cells (Shirakata et al., 1989) in a culture. Studies on transgenic mice carrying the X-reading frame controlled by its natural HBV enhancer/promoter sequences showed the development of preneoplastic lesions followed by malignant carcinomas at 8 ± 10 months of age (Kim et al., 1991) . Other studies using heterologous liver-speci®c promoters, such as a-1 antitrypsin and the antithrombin three-regulatory regions, failed to induce serious liver damage in transgenic mice, although X mRNAs were detected in liver tissues . The discrepancies in the results of these two experiments have not been reconciled.
Sp1 is a ubiquitous mammalian transcription factor belonging to a member of the C 2 -H 2 zinc-®nger family, thought to be involved in the regulation of a large number of genes (Kadonaga and Tjian, 1986) , including genes involved in proliferative responses (Lu et al., 1994) , extracellular matrix protein genes (Tamaki et al., 1995) , house-keeping genes (Kumar et al., 1995) and a number of growth factor genes (Chen et al., 1992) . Sp1 has also been implicated in the function of retinoblastoma gene (Rb) product which is known to regulate cell cycle progression and repress cell growth and dierentiations (Hagen et al., 1992; Horowitz et al., 1990) , suggesting that Sp1 may be involved in modulating transcription in response to the growth state of the cell. Sp1 binds to and stimulates transcription through the RCE motif (Kim et al., 1992) . A protease sensitive Sp1 negative regulator (Sp1-1), which inhibits Sp1 binding to the Sp1 binding site of the c-jun promoter, has recently been identi®ed (Chen et al., 1994) . These observations suggest that regulation of Sp1 functions may lead to changes of cell physiology.
An increase in Sp1-DNA complexes present on the Sp1 binding site during HBV-X expression lead to the suggestion that an increase in Sp1-DNA binding activity by HBV-X is modulated by phosphorylation. It has been suggested that in normal liver, Sp1 is phosphorylated, resulting in a decrease in its anity for DNA (Legget et al., 1995) . In de-dierentiated tissues, such as regenerating or new-born rat liver, Sp1 is less phosphorylated and exhibits increased DNA binding activity. Dephosphorylation of Sp1 results in a tenfold increase in the anity of Sp1 for its recognition sites. So, phosphorylation of Sp1 may be an important regulatory mechanism for controlling growth and dierentiation in vivo. Legget et al. (1995) have been able to demonstrate that serine/threonine kinase, casein kinase II is capable of phosphorylating the DNA binding domain of Sp1 and this phosphorylation results in a reduction in Sp1 DNA binding activity. Sp1 activity can also be induced by phosphatase treatment in the adult tissues examined. The dephosphorylation of Sp1 and the consequent increase in its DNA binding activity suggests that this process is a signi®cant regulatory mechanism during development (Legget et al., 1995) .
Dierent results were obtained in our experiment. Using nuclear extract from X and Sp1 expressed Schneider cells and from HepG2, HepG2(X) and HepG2-4X, it was demonstrated that X phosphorylated Sp1 in vivo and the binding of transcription factors including Sp1 to the Sp1 consensus sequences of pIG7 could be induced by phosphorylation of these extracts since dephosphorylation of the extracts using calf intestine phosphatase results in the decrease of trasnscription factors to its cognate DNA-binding site. Supershift assay using anti-Sp1 and anti-Sp3 antibodies reveals that these proteins to be the transcription factor Sp1 and Sp3. Phosphorylation of the proteins appeared to increase as a result of HBV-X expression in HepG2 cells which resulted in the increase of the transcription factors (Sp1 and Sp3) binding to its cognate sequences. Increasing Sp1 and Sp3 DNA binding activity by phosphorylation might be an important mechanism for regulating gene expression, and possibly bring about growth promotion during liver carcinogenesis. Sp1, Sp3 and Sp4 are human sequence-speci®c DNA-binding proteins with very similar structural features (Hagen et al., 1992; Kingstey and Winton., 1992) . Though Sp3 protein is expressed in various cell lines, Sp3 is not able to activate several Sp1 responsive promoters. Sp3 also failed to activate the reporter construct in Drosophila SL2 cells lacking endogeneous Sp factors (Hagen et al., 1994) . Instead Sp3 was suggested to repress Sp1 mediated activation by competing with Sp1 for their common binding sites. Since Sp3 as well as Sp1 showed the increased DNA-binding activity by HBV-X in HepG2(X) cell lines and decreased DNA-binding activity in dephosphorylation experiment, Sp3 might be involved in an important mechanism in regulating the IGF-II promoter 4. The experiments on the identi®cation of actual mechanisms of Sp3, in relation to Sp1 on IGF-II promoter 4 is under investigation in this lab.
Using the Drosophila cell line SL-2, we also showed that Sp1 when cotransfected with plG0-CAT, is able to activate transcription. Since Sp1 is an ubiquitously expressed transcription factor, an immediate question arises, whether all the genes that contain Sp1 binding sites are responsive to HBV-X. Since Sp1 does not bind to all the consensus sequences during a given promoter; the binding is selective in the activation of the gene (Daniel and Kim, 1996) . In addition, it is known that dierent activation domains of Sp1 molecules are responsible for dierent functions (Courey and Tjian, 1992) . The interactions between Sp1 molecules at dierent sites on genes as well as interactions of Sp1 with other nuclear factors indicate that Sp1 functions dierently in a gene speci®c manner (Li et al., 1991) . Recently, v-raf was reported to activate the murine rep-3b promoter through the modi®cation of the bound Sp1 without aecting Sp1 binding to the promoter (Miltenberger et al., 1995) . In this case the modi®cation of Sp1 may lead to speci®c gene activation without involving the interaction of Sp1 with other proteins. So, it is possible that HBV-X activates the genes which contain an Sp1 binding site in a gene-speci®c manner by interacting with the speci®c nuclear factors, speci®c Sp1 domain or modifying Sp1 itself. In our experiment where the IGF-II promoter transactivations caused by X, Sp1 phosphorylation by X is involved in enhancement of DNA binding activities of Sp1, which resulted in the up-regulation of IGF-II transcription.
Various mutants of HBV-X were constructed in order to investigate the eect of Sp1 mediated transcriptions on HBV-X mutants in HepG2 cells. Using Chou-Fasman's and Garnier's method, the adr subtype of HBV-X amino acid sequences was analysed for hydrophilicity and secondary structure (Garnier et al., 1978; Lo et al., 1988) . The HBV-X protein was found to have four a-helixes, or coiled regions, and four b-sheet regions (Figure 10a) . In order to determine the regions needed for X-mediated transactivating activity, ®ve N-terminal and four C-terminal serial deletion mutants were constructed. The ®rst N-terminal deletion mutant (ND-1), which removed nine amino acids, did not exhibit any activity decrease, which indicates that the ®rst helix is not important for full activity, but the larger, internal deletions (ND-2, ND-3, ND-4), which showed approximately 70*80% transactiviting activity compared to the wild type, are important for transactivating activity (Figure 10a) .
These results suggest that the second turning region and the helix coil region are important for HBV-X activity, but not as critical as are the second beta sheet and the third turning region deletions, as indicated by the ND5 result which showed more than an 80% decrease of HBV-X activity. In the analysis of the C-terminal deletion mutants, amino acids 136*154 could be deleted from HBV-X without aecting transactivating activity. Since CD-1 did not show any decrease in transactivating activity and CD-2 showed an approximate 80% transactivating activity while CD-3 showed a more than 80% loss of HBV-X activity, the ®ve amino acids (a.a.131 ± a.a.135) (V, F, V, L, G) appeared to be important for the transactivating activity of HBV-X. These ®ve amino acids are well conserved in all eleven known subtypes of human HBV-X, WHV-X, and DHBV-X (Lo et al., 1988) . These results are dierent from previous results for pSV2CAT and pMAM-neoCAT as reporters, where seven amino acids (G, C, R, H, K, L, V) in the deleted regions of CD2 (amino acids 136*142) are important for all transactivating activity ( Figure  10B ) . These results are also dierent from work on the X-response to the TGFb-1 promoter, which showed that the transcription factor Egr-1 is responsible for X-responsiveness. Seven amino acids (amino acids 136 to 142) of the Xprotein are important for Egr-1 activation of the TGFb-1 promoter ( Figure 10B ) (Yoo et al., 1996) . These seven amino acids (G, C, R, H, K, L) are composed of basic residues ( Figure 10B ). Though the strong basic regions have been described as important functional regions in viral and cellular transcription factors (Stemler et al., 1990) , the ®ve amino acids (V, F, V, L, G) which are important for Sp1 mediated transactivation of X-activity show hydrophobic residues. More systematic studies need to be done for the identi®cation of the structures responsible for the transactivating activity of HBV-X. Studies are in progress to con®rm HBV-X functions in an in vitro system in which all mutants are translated in vitro, using wheatgerm lysate for generating mutant HBV-X.
Insulin-like growth factor II (IGF-II) is a fetal growth factor which is known to act on fetal development and dierentiation (Daughaday et al., 1989) . High levels of IGF-II mRNAs have been reported in many tumors and tumor cell lines including Wilm's tumors and rhabdomyosarcomas (Beckwith et al., 1990) , whose expression is owed to promoters three and four preceding exons 5 and 6, respectively, which induces the expression in fetal liver. Also in primary liver cancers and some cirrhotic tissues surrounding the liver cancer, fetal types of IGF-II transcripts are expressed (Cariani et al., 1988) . The traditional views that growth factors promote cell division and inhibit dierentiation has been challenged by recent observation that insulin-like growth factors (IGF-I and IGF-II) are involved in facilitating myoblast dierentiation in vitro Florini and Ewton, 1992) and enhancement of muscle growth and regeneration in vivo (Coleman et al., 1995) . Endogeneous IGF-II functions as a critical survival factor during the transition from proliferating to dierentiating myoblasts (Stewart and Rotwein, 1996) . It has also been reported that IGFII functions as surviving factor in N-myc deregulated hepatocyte apoptosis, a frequent event in hepadnavirus oncogenesis (Veda and Ganem, 1996; Yang et al., 1996) . The IGF-II might fuction as a surviving factor by preventing the programed cell death triggered by deregulated N-myc expression in the development of virus-induced hepatoma.
Involvement of hepatitis B virus on the IGF-II expression in the pathogenesis of cirrhotic/noncirrhotic chronic liver disease to hepatocellular carcinoma has been suggested (Carolyn et al., 1991) . A recent study has shown that 84% of HBV carrier patients with primary hepatocellular carcinoma were HBV-X Ag positive in their tumor cells (Wang et al., 1991) . Although many experimental results suggested the close association between hepatitis B virus and hepatocellular carcinoma, the contribution of HBV to pathogenensis is not known. The elevation of IGF-II expression in HCCs from HBV-infected but not uninfected patients suggest that HBV may stimulate IGF-II expression (D'Arville et al., 1991) .
Further work showed that a correlation between IGF-II and HBXAg expression by immunohistochemistry (Su et al., 1994) suggesting that IGF-II can be a natural target of HBXAg-mediated transactivation. However, the inverse correlation between IGF-II and WHV RNA levels in liver and tumors suggested that IGF-II can be made independent of viral replications (Su et al., 1994) . But, in human HBV, the mode of action of transactivator X could be dierent from WHV-X (CE Rogler; personal communications). Here we report the direct involvement of human HBV-X on the activation of the fetal form IGF-II (P4) during the formation of HCC. Together with the evidence that the human HBV-X is produced from a viral template integrated into the host genome during chronic infection (Wollersham et al., 1988) and the expression of the fetal form IGF-I correlates well with that of HCC formation, the experimental evidence of direct involvement of human HBV-X on the activation of the fetal form IGF-II strongly supports the hypothesis that IGF-II plays an important role in the pathogenesis of HBVassociated chronic liver disease, including primary hepatocellular carcinoma.
Materials and methods
Cell Culture, DNA Transfection and CAT assays Human hepatoma cells, Hep3B, PLC/PRF/5, and HepG2 were grown in a minimal essential medium supplemented with 10% fetal bovine serum. Human lung adenocarcinoma (A549) cells were grown in Dulbecco's modi®ed Eagle's medium with a high glucose content supplemented with 5% fetal bovine serum. The rhabdomyosarcoma cell line (RD), an RMS cell line with an Arg to Trp mutation at codon 248 of p53 and expressing a high level of p3 and p4 promoter driven fetal IGF-II transcripts obtained from American Type Culture Collection (ATCC) were grown in a minimal essential medium supplemented with 10% fetal bovine serum. Transfections were carried out by the CaPO 4 precipitation method (Graham et al., 1973) . The CaPO 4 -DNA coprecipitate was established by overnight incubation. After glycerol shock the cells were further incubated for 48 h in a complete medium. The cells were then harvested and extracts were assayed for CAT activity according to the method of Gorman (Gorman et al., 1982) . Quantitative results were calculated by excising spots corresponding to nonacetylated and acetylated forms from the TLC plates, which were then counted in a liquid scintillation spectrophotometer (Beckman Co., USA).
Plasmid Constructions
Adr subtype HBV DNA was isolated from HBV-infected Korean patients (Kim and Kang, 1984) . The intact X gene was prepared from the pHBV315-dimer plasmid which has two copies of HBV DNA cloned into the BamHI site of pBR322. All plasmids (XE-1, ND1*5, and CD1*4) used for the expression of native and mutant X-genes in eukaryotic cells were constructed by cloning the X-ORF insert into the SalI site of pMAM-neo (Clontech, Ca., USA) .
The 540 bp NruI-BstEII fragment, which contains the fourth promoter region of the human IGF-II gene, was subcloned into pGEM4-SV0CAT (Promega, Wis., USA) and was designated pIG0. The deletion mutant series of the fourth promoter of the human IGF-II gene was constructed by PCR amplication using oligonucleotides designed to generate ends with HindIII and XbaI restriction sites. The PCR product was then cloned into pGEM-SV0CAT, which was cut with the same enzymes (Hyun et al., 1993) , and puri®ed in two sequential CsCl centrifugation steps.
Isolation of RNA and Northern blot analysis
Total cellular RNA extraction was performed as described (Daughaday et al., 1989) . After homogenizing the cells in 6 M guanidine thiocyanate, 0.5% sarkosyl, and 1 mM bmercaptoethanol, the cell lysate was loaded onto a 3 ml cushion of 5.7 M C S C1 in 1 mM EDTA and centrifuged at 35 000 r.p.m. at 208C in SW41 (Beckman) for 24 h. The RNA pellet was resuspended in RNase-free water and ethanol-precipitated with 0.3 M sodium acetate (pH 5.0). 30 mg of the total RNA was fractionated on a 2.2 M formaldehyde-denaturing agarose gel and transferred onto Nylon membrane. Hybridization was carried out following the established protocol (Daughaday et al., 1989) .
Analysis of Sp1 binding
Sp1 binding was analysed by using a buer containing 20 mM HEPES (pH 7.9), 1 mM MgCl 2 , 4% Ficoll, 0.5 mM DTT, 50 mM KCl, 2 mg poly dIdC and 1 ml 32 P-labeled probe and 2 ng puri®ed Sp1 protein. Binding complexes were analysed by electrophoresis on a 5%, 0.5 X trisborate EDTA-polyacrylamide gel. The puri®ed Sp1 was purchased from Santa Cruz Biotechnology Co., U.S.A. For gel shift analysis using the IG5 and IG7 probes, plasmids pIG5 and pIG7 were digested with HindIII and SmaI, dephosphorylated, labeled with 32 P and puri®ed (Hyun et al., 1993) . The oligonucleotides for the IG8 probe (736 to 717) were synthesized, annealed and end labeled. As a competitor, synthesized Sp1 consensus sequences (5'-ATTCGATCGGGGGGGGGCGAG-3') were used.
Nuclear extracts preparation
Nuclear extracts from cells transfected with p53 or Sp1 expression vectors (pCMVp53 or pSp1) were prepared as described (Nancy and Douglas, 1991) . 5610 6 to 10 7 cells were washed with ice-cold phosphate buered saline(PBS) and scraped cells were collected using 1.5 ml cold PBS. Cells were pelleted for 10 s and resuspended in 400 ml of cold swelling buer (Buer S; 10 mM HEPES-KOH, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) on ice for 10 min and then vortexed for 10 s. Samples were centrifuged for 10 s using Eppendorf centrifuge and the supernatant was discarded. The pellets were resuspended in 100 ml of cold high salt extraction buer (Buer E; 20 mM HEPES-KOH (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 0.2 mM EDTA, 0.5 mM DTT and 0.2 mM PMSF) and incubated on ice for 20 min. Cellular debris was removed by centrifugation for 2 min at 48C and the supernatant fraction was dialyzed against the dialysis buer (Buer D; 5 mM HEPES-KOH (pH 7.9), 25% glycerol, 1.5 mM MgCl 2 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF).
Nuclear Extract Dephosphorylation
The dephosphorylation of extracts was carried out in 25 mM HEPES, pH 7.5, 34 mM KCI, 50 mM MgCl 2 at 308C for 5 min, then 15 min on ice with calf intestinal alkaline phosphatase (1 unit/50 mg of nuclear extract). The dephosphorylation reaction was stopped by the addition of a mixture of inhibitors to ®nal concentrations of 10 mM NaF, 10 mM sodium vanadate, 10 mM potassium pyrophosphate, and 5 mM sodium phosphate. The inhibitors were added to the extract before the 308C incubation for the mock dephosphorylation reactions.
Expression and Puri®cation of GST-X
Overnight cultures of E. coli, transformed with pGST-X were diluted into 1 : 100 in 800 ml of LB medium containing ampicillin (100 ml/ml) and grown at 378C until the OD 600 of the culture medium became 0.7, then isopropyl-b-D-thiogalactopy ranoside (IPTG) was added to 1 mM. After a further 7 h growth at 378C, the cells were harvested by centrifugation, and the pellet was resuspended in 300 ml of 50 mM Tris-HCl (pH 8.0), 10 mM EDTA and 100 mM NaCl. Then the suspension was sonicated (Branson soni®er 450, 1 min pulsed type with 0.5 inch probe). The lysate was then centrifuged at 15 000 g for 20 min. The pellet was resuspended in 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 100 mM NaCl, and 1% Triton X-100 and then the suspension was centrifuged. The pelleted inclusion body was resuspended in elution buer (50 mM Tris-HCl (pH 8.0), 8 M urea, 10 mM EDTA, and 10 mM DTT) and loaded onto Sephacryl S-200 column (3.06110 cm), (Pharmacia LKB Biotechnology, Inc.) which had been equilibrated in elution buer.
The column was eluted with elution buer (0.4 ml/min) at room temperature. All following steps were performed at 48C. The GST-X fraction was dialyzed in 4 M urea containing 50 mM Tris-HCl (pH 8.0), 1 mM DTT for 4 h and the urea concentration was decreased in steps, 2 M, 1 M, 0.5 M and 0.2 M for refolding. Finally, the GST-X was dialyzed in MTPBS (150 mM NaCl, 16 mM Na 2 HPO 4 and 4 mM NaH 2 PO 4 , pH 7.3).
GST-fusion protein anity chromatography and analysis of protein complexes
The renatured GST-X was absorbed with 500 ml of 50% glutathione agarose beads (Sigma) for 1 h at 48C on a rotating platform. The beads were washed three times and suspended in MTPBS. The 50 ml of GST-X-agarose beads were incubated with Sp1 or p53, prepared from nuclear extract, for 30 min at 48C and then washed several times with MTPBS. The bound and¯ow-through fractions were subjected to SDS±PAGE on a gel containing 11% polyacrylamide and transfered to nitrocellulose membrane for Western blotting. The Western blotting was performed with mouse monoclonal anti-p53-antibodies (AB-1, 1 : 1000) and rabbit polyclonal anti-Sp1-antibodies (PEP2, 1 : 1000) (Santa Cruz, Biotechnology Co., USA) by the manufacturers' recommended method.
Supershift experiment
32 p-labelled Sp1 consensus probe described above was incubated for 10 min at room temperature with 10 mg of nuclear protein extracts prepared from HepG2, HepG2(X) or HepG2-4X cells. At the end of this period, binding buer was added and incubation was continued for an additional 20 min at room temperature. The complexes thus formed were incubated for 30 min in the presence of 1 mg of Sp1 or Sp3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The resulting DNA-protein complexes were analysed after electrophoresis on a 4% polyacrylamide gel.
In vivo phosphorylation of Sp1
In order to determine the HBV-X phosphorylation of Sp1, pSp1 transfected or pSp1, pCMV-X double transfected Schneider SL-2 cells were grown in Schneider media (Life, Technologies, Inc.). SL-2 cells were starved in 3 ml of phosphate free media (150 mM, 5 mM MgCl 2 , 5 mM KCl, 2 mM glutamine, 1.8 mM glucose in 10 mM Tris-Acetate buer (pH 7.4), 2% dialyzed FCS) for 1 h and the cells were labelled with 1 mCi/ml [ 32 p]orthophosphate (Amersham). After harvesting, the collected cells were lysed with IP-buer (1% Triton-X100, 20 mM Tris-HCl buer (pH 7.5) containing protease inhibitors (10 mg/ml leupeptin, 1 mM PHSF) and phosphatase inhibitor (orthovanadate)). Radiolabeled Sp1 was immunoprecipitated with polyclonal Sp1 antibody (Santa Cruz cpy.), resolved on 8% SDS ± PAGE and autoradiographed. In order to con®rm, stable HBV-X transfectants (HepG2-4X), transient HBV-X transfectants (HepG2 (X)), and HepG2 control cells (5610 6 ) were incubated in phosphate free DMEM supplemented with 2% dialyzed fetal calf serum for 1 h and further incubated for 2 h in 2.5 ml of phosphate free DMEM with 1 mCi/ml [ 32 p]orthophosphate (Amersham). After labeling, nuclear extracts of cells were prepared as mentioned above. Immunoprecipitaton was performed with 10 ml of polyclonal anti-Sp1 antibody (Santa Cruz Biotechnology, Inc.) and 30 ml of protein A-agarose (Sigma) in a 800 ml of 1 : 10 mixture of nuclear extracts and immunoprecipitation buer (150 mM NaCl, 50 mM Tris, pH 8.0, 1 mM PMSF, 10 mg/ml leupeptin, 3 mg/ml of aprotinin, 0.5 mM sodium orthophosphate). Labeled protein was eluted by boiling the sample in Laemmli buer for 3 min, resolved on 7.5% SDS ± PAGE and analysed by autoradiography.
Immuno-blot analysis
To detect the Sp1 or p53 in the cell extract, pSp1 or pCMVp53 transfected HepG2 cells and untransfected HepG2 cells were harvested 24 h after transfection. The whole cell extracts were suspended in Laemmli buer, heated at 1008C for 10 min and electrophoresed on SDSpolyacrylamide gel along with molecular weight markers. After electrophoresis, proteins were electroblotted onto the nitrocellulose ®lter paper for immunoblotting. For antibodies, monoclonal antibodies against Sp1 or p53 (purchased from Santa Cruz Biotechnology Co., USA) were used. Horseradish peroxidase-conjugated rabbit antimouse IgG was used as a secondary antibody. Substrate (bromochloroindolyl phosphate/nitro blue tetrazolium) was used for color reactions.
